statistiche ricercatore

Continente	#
NA - Nord America	1.274
AS - Asia	629
EU - Europa	367
SA - Sud America	79
Continente sconosciuto - Info sul continente non disponibili	33
AF - Africa	9
OC - Oceania	9
Totale	2.400

Nazione	#
US - Stati Uniti d'America	1.237
SG - Singapore	240
CN - Cina	128
IT - Italia	107
VN - Vietnam	85
BR - Brasile	63
DE - Germania	44
GB - Regno Unito	40
AT - Austria	39
HK - Hong Kong	38
BD - Bangladesh	30
CA - Canada	23
ID - Indonesia	23
FR - Francia	22
PL - Polonia	22
JP - Giappone	20
FI - Finlandia	16
IN - India	16
TR - Turchia	15
SE - Svezia	14
RU - Federazione Russa	12
ES - Italia	10
UA - Ucraina	9
AR - Argentina	8
AU - Australia	8
NO - Norvegia	7
PK - Pakistan	7
BE - Belgio	5
CH - Svizzera	5
IQ - Iraq	5
LT - Lituania	5
MX - Messico	5
ZA - Sudafrica	5
NL - Olanda	4
MY - Malesia	3
PA - Panama	3
EC - Ecuador	2
HN - Honduras	2
IE - Irlanda	2
JO - Giordania	2
KE - Kenya	2
KG - Kirghizistan	2
NP - Nepal	2
PH - Filippine	2
PS - Palestinian Territory	2
TT - Trinidad e Tobago	2
TW - Taiwan	2
VE - Venezuela	2
AL - Albania	1
BO - Bolivia	1
CO - Colombia	1
EE - Estonia	1
EG - Egitto	1
GR - Grecia	1
IL - Israele	1
JM - Giamaica	1
KZ - Kazakistan	1
NZ - Nuova Zelanda	1
PR - Porto Rico	1
PY - Paraguay	1
QA - Qatar	1
SA - Arabia Saudita	1
SK - Slovacchia (Repubblica Slovacca)	1
SY - Repubblica araba siriana	1
TH - Thailandia	1
TN - Tunisia	1
UY - Uruguay	1
UZ - Uzbekistan	1
Totale	2.367

Nome	#
Anti-Parkinsonian and anti-dyskinetic profiles of two novel potent and selective nociceptin/orphanin FQ receptor agonists	314
Safinamide differentially modulates in vivo glutamate and GABA release in the rat hippocampus and basal ganglia	302
Therapeutic potential of RGS4 blockade in movement disorders	250
Leucine-rich repeat kinase 2 (LRRK2) inhibitors differentially modulate glutamate release and Serine935 LRRK2 phosphorylation in striatal and cerebrocortical synaptosomes	221
NOP receptor ligands and Parkinson’s disease	209
Discovery and Structure-Activity Relationships of Nociceptin Receptor Partial Agonists That Afford Symptom Ablation in Parkinson's Disease Models	170
6-Hydroxydopamine lesion and levodopa treatment modify the effect of buspirone in the substantia nigra pars reticulata	168
Striatal and nigral muscarinic type 1 and type 4 receptors modulate levodopa-induced dyskinesia and striato-nigral pathway activation in 6-hydroxydopamine hemilesioned rats	163
Molecular and imaging prodromal markers of dopamine neuron degeneration in animal models of Parkinson’s disease: pathophysiology and clinical perspectives	156
Safinamide inhibits in vivo glutamate release in a rat model of Parkinson's disease	154
Safinamide Modulates Striatal Glutamatergic Signaling in a Rat Model of Levodopa-Induced Dyskinesia	152
Regulator of G-Protein Signalling 4 (RGS4) negatively modulates nociceptin/orphanin FQ opioid receptor signalling: Implication for L-Dopa-induced dyskinesia	141
Totale	2.400

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2021/2022	91	0	0	4	2	2	14	8	14	6	7	11	23
2022/2023	171	14	26	11	22	27	24	6	5	19	0	11	6
2023/2024	93	8	4	4	6	8	13	4	11	2	5	4	24
2024/2025	367	5	9	37	5	27	67	2	16	46	65	48	40
2025/2026	1.213	134	34	69	136	202	78	148	80	103	130	76	23
2026/2027	123	33	42	48	0	0	0	0	0	0	0	0	0
Totale													2.400

SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara